122 related articles for article (PubMed ID: 38830971)
1. PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC.
Kaufman B; Taha T; Abramov O; Zohar Y; Mhameed K; Cohen O; Porgador A; Elkabets M; Billan S
NPJ Precis Oncol; 2024 Jun; 8(1):126. PubMed ID: 38830971
[TBL] [Abstract][Full Text] [Related]
2. The clinicopathological significance of PD-L1 expression assessed by the combined positive score (CPS) in head and neck squamous cell carcinoma.
Wusiman D; Guo L; Huang Z; Li Z; Liu S; Ying J; Li W; An C
Pathol Res Pract; 2022 Aug; 236():153934. PubMed ID: 35691098
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
5. PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.
Müller T; Braun M; Dietrich D; Aktekin S; Höft S; Kristiansen G; Göke F; Schröck A; Brägelmann J; Held SAE; Bootz F; Brossart P
Oncotarget; 2017 Aug; 8(32):52889-52900. PubMed ID: 28881780
[TBL] [Abstract][Full Text] [Related]
6. Anti-PD1/PD-L1 monotherapy vs standard of care in patients with recurrent or metastatic head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials.
Zhu P; Wang Y; Zhang W; Liu X
Medicine (Baltimore); 2021 Jan; 100(4):e24339. PubMed ID: 33530227
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma.
Ngamphaiboon N; Chureemas T; Siripoon T; Arsa L; Trachu N; Jiarpinitnun C; Pattaranutaporn P; Sirachainan E; Larbcharoensub N
Med Oncol; 2019 Jan; 36(2):21. PubMed ID: 30666437
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.
Strati A; Koutsodontis G; Papaxoinis G; Angelidis I; Zavridou M; Economopoulou P; Kotsantis I; Avgeris M; Mazel M; Perisanidis C; Sasaki C; Alix-Panabières C; Lianidou E; Psyrri A
Ann Oncol; 2017 Aug; 28(8):1923-1933. PubMed ID: 28838214
[TBL] [Abstract][Full Text] [Related]
9. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical study of Programmed Cell Death Ligand 1 (PDL1) expression by combined positive score using 22C3 clone in head and neck squamous cell carcinomas, its correlation with clinicopathological features and outcome.
Gangadhar P; Ilanthodi S; Shetty R; Shenoy KK; Philipose TR
J Oral Maxillofac Pathol; 2024; 28(1):29-36. PubMed ID: 38800420
[TBL] [Abstract][Full Text] [Related]
11. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide open reading frame profiling identifies fibroblast growth factor signaling as a driver of PD-L1 expression in head and neck squamous cell carcinoma.
Mann JE; Smith JD; Kulkarni A; Foltin SK; Scheftz EB; Murray IR; Gensterblum-Miller E; Brummel CV; Bhangale A; Hoesli RC; Brenner JC
Oral Oncol; 2023 Nov; 146():106562. PubMed ID: 37666053
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions.
Kao HF; Lou PJ
Head Neck; 2019 Oct; 41 Suppl 1():4-18. PubMed ID: 31573752
[TBL] [Abstract][Full Text] [Related]
14. A computed tomography-based radiomics signature for predicting expression of programmed death ligand 1 in head and neck squamous cell carcinoma.
Zheng YM; Yuan MG; Zhou RQ; Hou F; Zhan JF; Liu ND; Hao DP; Dong C
Eur Radiol; 2022 Aug; 32(8):5362-5370. PubMed ID: 35298679
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of PD-L1 expression in head and neck squamous cell carcinoma: An institutional experience from India.
Kala PS; Thapliyal N; Pant B; Sharma N; Pandey HS
Pathol Res Pract; 2024 Feb; 254():155133. PubMed ID: 38306860
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity.
Karabajakian A; Bouaoud J; Michon L; Kamal M; Crozes C; Zrounba P; Auclair-Perossier J; Gadot N; Attignon V; Le Tourneau C; Benzerdjeb N; Fayette J; Saintigny P
Oral Oncol; 2021 Aug; 119():105368. PubMed ID: 34111704
[TBL] [Abstract][Full Text] [Related]
17. PD-L1-positive circulating endothelial progenitor cells associated with immune response to PD-1 blockade in patients with head and neck squamous cell carcinoma.
Su NW; Dai SH; Hsu K; Chang KM; Ko CC; Kao CW; Chang YF; Chen CG
Cancer Immunol Immunother; 2024 Jan; 73(1):3. PubMed ID: 38175307
[TBL] [Abstract][Full Text] [Related]
18. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC).
de Ruiter EJ; Mulder FJ; Koomen BM; Speel EJ; van den Hout MFCM; de Roest RH; Bloemena E; Devriese LA; Willems SM
Mod Pathol; 2021 Jun; 34(6):1125-1132. PubMed ID: 32759978
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.
Burtness B; Rischin D; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Brana I; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesia R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Ge J; Swaby RF; Gumuscu B; Harrington K
J Clin Oncol; 2022 Jul; 40(21):2321-2332. PubMed ID: 35333599
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression in recurrent or metastatic head and neck squamous cell carcinoma in China (EXCEED study): a multicentre retrospective study.
Lu H; Kuang D; Zhou P; Zeng J; Xia Q; Wang J; Duan P; Jiang L; Zang S; Jin Y; Jiang X; Li J; Tang W; Zhou J; Chen J; Ying J
J Clin Pathol; 2023 Nov; ():. PubMed ID: 37968103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]